Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.48 |
| ▸ | NPC1 | O15118 | 8/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | RPA1 | P27694 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMO | O15229 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748788 | 0.81 | RAB9A (0.56) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15748796 | 0.73 | MAPT (0.47) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL15748776 | 0.70 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL3499262 | 0.69 | GABRA2 (0.46) | RAB9ANPC1SMN1; SMN2MAPTAHR | |
| SCHEMBL7618521 | 0.69 | KDR (0.77) | RAB9ANPC1SMN1; SMN2MAPTKDR | |
| SCHEMBL28016016 | 0.65 | MAP4K4 (0.58) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL23657692 | 0.65 | KDR (0.59) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL7616707 | 0.65 | KDR (1.00) | RAB9ANPC1SMN1; SMN2MAPTKDR | |
| SCHEMBL30613542 | 0.64 | KDR (0.44) | RAB9ANPC1SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL20723060 | 0.64 | PIM1 (0.52) | RAB9ANPC1SMN1; SMN2MAPTKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081820-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PSYCHOGENICS INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | CFTR, CLCN2, SLC26A4 | RAB9A 185/4885NPC1 63/4885SMN1; SMN2 3872/4885 |
| US-20130109677-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | RAB9A 1166/4885NPC1 110/4885SMN1; SMN2 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.